Results 151 to 160 of about 86,262 (260)
Novel use of telitacicept in primary immune thrombocytopenia: a case report. [PDF]
Wang Y +6 more
europepmc +1 more source
ABSTRACT Extranodal marginal zone lymphoma (EMZL) represents a unique paradigm among indolent B‐cell neoplasms, in which lymphomagenesis is frequently driven by chronic antigenic stimulation within tissue‐specific microenvironments. Persistent infectious or autoimmune triggers promote the development of ectopic lymphoid tissue and sustain B‐cell ...
Mamdouh Skafi +15 more
wiley +1 more source
Short- and long-term outcome of neonates with thrombocytopenia from maternal immune thrombocytopenia. [PDF]
Sorin B +21 more
europepmc +1 more source
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto +12 more
wiley +1 more source
ABSTRACT Introduction The GTH‐AHA‐EMI study showed that emicizumab reduces bleeding in patients with acquired haemophilia A (AHA). However, 22 clinically relevant new bleeds (CRNB) occurred in 14 of the 47 study patients, most of which required haemostatic treatment.
Halet Türkantoz +11 more
wiley +1 more source
Safety and efficacy of daratumumab in immune thrombocytopenia. [PDF]
Tsykunova G +15 more
europepmc +1 more source
ABSTRACT Aim The therapeutic significance of recombinant a disintegrin‐like and metalloprotease with thrombospondin type 1 motif 13 (rADAMTS13) in acute‐on‐chronic liver failure (ACLF) remains unclear. We aimed to investigate the therapeutic effects of rADAMTS13 in a murine model of ACLF‐like liver injury.
Jun‐ichi Hanatani +9 more
wiley +1 more source
Real-world investigation of platelet apoptosis for mechanistic insights into severe immune thrombocytopenia and bleeding. [PDF]
Tyagi T +5 more
europepmc +1 more source
This bicentric study of 95 CCLE patients shows SLE prevalence (21.1%–31.6%) varies significantly by classification criteria. Arthralgia was a consistent independent risk factor across all systems. Our findings support the implementation of systematic risk‐stratified screening protocols for CCLE patients, with particular attention to joint symptoms and ...
Noureddine Litaiem +4 more
wiley +1 more source

